After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)

Group 1 - I-Mab Sponsored ADR (IMAB) has experienced significant selling pressure, resulting in a 19.7% decline over the past four weeks, but analysts anticipate better earnings than previously predicted [1] - The stock is currently in oversold territory, indicated by an RSI reading of 29.26, suggesting that the heavy selling may be exhausting itself [5] - There has been a 37.3% increase in the consensus EPS estimate for IMAB over the last 30 days due to a strong agreement among sell-side analysts, which typically correlates with price appreciation [7] Group 2 - IMAB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8]